“The effectiveness of semaglutide, sold as the diabetes drug Ozempic and weight-loss drug Wegovy, contributed to its overwhelming popularity and huge demand. This led to global shortages throughout 2022–23, which maker Novo Nordisk says will likely continue into this year. The shortage has particularly affected type 2 diabetics who rely on semaglutide to keep their blood glucose levels under control and are left searching for suitable alternatives.

Researchers at The Florey Institute in Melbourne, Australia, may have discovered a way of addressing the critical shortage, developing a method of production of a drug analog that has the same therapeutic effects as semaglutide. Their novel production method is not only cost-effective and simpler but produces far more of the drug.”

From New Atlas.